Matthew Spencer and James Legg, representing Adaptive Biotechnologies Corporation, successfully defended European Patent No. 2 364 368 at the European opposition hearing on 16 November 2016.
The Patent, which had been opposed by three opponents, provides broad protection for immune profiling using next-generation sequencing (NGS).
Adaptive Biotechnologies Corporation is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Its platforms include immunoSEQ®, a research-based assay, and clonoSEQ®, a diagnostic assay for the monitoring of patients with lymphoid cancers.